Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor

  • Antiviral Res. 2006 Jun;70(2):17-20. doi: 10.1016/j.antiviral.2005.12.006.
G Sévigny  1 ,  B Stranix ,  B Tian ,  A Dubois ,  G Sauvé ,  C Petropoulos ,  Y Lie ,  N Hellmann ,  B Conway ,  J Yelle
Affiliations
  • 1. Procyon Biopharma Inc., Montreal, Canada.
PMID: 16473417 DOI: 10.1016/j.antiviral.2005.12.006
Abstract

The HIV Protease Inhibitor P-1946 is a member of a novel family of l-Lysine derivatives. The compound is a specific HIV-1 protease inhibitor that has potent and selective in vitro Antiviral activity (EC50 152 nM) against a range of isolates resistant to commercially available Protease Inhibitors. The presence of at least four primary and four secondary drug resistance mutations is required to achieve greater than four-fold resistance to P-1946. P-1946's favorable resistance profile makes it a good lead for the development of new agents active against existing PI-resistant virus in treatment-experienced patient.

Products